What Ibuflam Lichtenstein Treats: Main Uses and Benefits

Ibuflam Lichtenstein is applied across therapeutic domains that involve symptoms related to physical discomfort and systemic imbalance, where supportive symptom management is appropriate. It is commonly used to help manage symptoms in conditions characterized by periods of heightened discomfort.

Symptomatic Relief for Acute Pain and Discomfort

The medication plays a role in managing acute episodes of mild to moderate pain stemming from various sources. This includes supporting the management of common manifestations such as headache, toothache, and the disruptive discomfort of primary dysmenorrhea. It provides support that helps ease the overall symptom burden, assisting patients in coping more steadily with symptom fluctuations.

Moderating Inflammation, Swelling, and Fever

Ibuflam Lichtenstein is relevant for easing symptoms related to inflammatory states, such as the swelling and stiffness associated with osteoarthritis and rheumatoid arthritis. It is also applied when short-term symptomatic assistance is needed for common soft tissue injuries like sprains and strains. Furthermore, it supports the patient during difficult episodes by helping with symptoms related to fever and general body aches during illnesses like the flu, supporting general well-being during acute symptomatic periods.

---

Quick Fact: Supports Management of Pain, Inflammation, and Fever

Eligibility for Ibuflam Lichtenstein is strictly defined by official regulatory documentation and patient health status, classifying populations as allowed, restricted, or prohibited.

Contraindications (Must Not Use)

Contraindicated Group	Eligibility Rule (Regulatory Basis)
Severe Organ Failure	Severe heart failure (NYHA Class IV), severe hepatic failure, or severe renal failure [1.1, 1.3].
GI Disease	Active, or history of, recurrent peptic ulceration or gastrointestinal haemorrhage [1.2, 1.6].
Hypersensitivity	Known allergy to Ibuprofen, aspirin, or other NSAIDs [1.2, 1.6].
Pregnancy	Last trimester of pregnancy (starting at 30 weeks gestation) [2.3].
CABG Surgery	Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery [1.6].

Restricted or Conditional Use

Use is allowed only with caution and monitoring in specific populations:

• The Elderly: Have an increased risk of serious adverse reactions, requiring treatment with the lowest effective dose for the shortest duration [1.1, 1.7].
• Mild/Moderate Organ Impairment: Patients with mild to moderate renal or hepatic impairment must use the lowest dose, with function monitored [1.7].
• Cardiovascular Conditions: Patients with uncontrolled hypertension or mild to moderate heart failure (NYHA Class II-III) require careful consideration, and high daily doses (2400 mg/ day) must be avoided [1.7, 3.6].

Age and Pregnancy Status

Ibuflam Lichtenstein is generally allowed for adults and adolescents (typically 12 years). Pediatric use is restricted by specific minimum age and body weight thresholds (e.g., contraindicated below 20 kg) [1.7]. During pregnancy, use should be avoided after 20 weeks gestation, and is strictly prohibited in the third trimester; use in women attempting to conceive is not recommended [1.5, 2.3].

Interactions with other medicines and products

Ibuflam Lichtenstein, containing Ibuprofen, has officially documented interaction patterns that primarily fall into classifications of pharmacodynamic risk and altered drug clearance, as outlined in regulatory sources.

Contraindicated Combinations and Major Restrictions:

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including other ibuprofen products or COX-2 inhibitors, is contraindicated due to a documented increase in serious gastrointestinal and cardiovascular risk. The use of this medication for peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery is also restricted.

Interactions Affecting Bleeding and GI Risk:

Combining Ibuflam Lichtenstein with Anticoagulants (like Warfarin), Oral Corticosteroids, Antiplatelet agents, or SSRIs may result in an additive risk of bleeding or gastrointestinal ulceration. Similarly, consumption of alcohol (ethanol) concurrently increases the risk of serious gastrointestinal hemorrhage.

Interactions Affecting Drug Exposure and Clearance:

Ibuprofen may reduce the renal clearance of substances such as Lithium and Methotrexate, which can lead to elevated plasma concentrations and potential toxicity of the co-administered drug. The medication may also diminish the antihypertensive or natriuretic effect of Diuretics and ACE-inhibitors/ARBs.

Timing-Based Rule for Aspirin:

When co-administering with cardioprotective low-dose aspirin, a specific timing separation is required—administer Ibuflam Lichtenstein at least 30 minutes after or 8 hours prior to the aspirin dose to prevent interference with its antiplatelet effect.

How Ibuflam Lichtenstein works

Molecular Action: Non-Selective Enzyme Inhibition

Ibuflam Lichtenstein initiates its pharmacodynamic action by acting as a non-selective inhibitor that reversibly blocks the activity of the Cyclooxygenase enzymes ( COX-1 and COX-2). This fundamental molecular interaction immediately suppresses the transformation of arachidonic acid into prostaglandins and related mediators, modifying an early, critical step in the eicosanoid signaling cascade.

Dual Pathway Modulation: Nociception and Thermoregulation

The consequence of enzyme inhibition is twofold, affecting both central and peripheral systems. Peripherally, the reduction in prostaglandins decreases the sensitization of nociceptors (peripheral sensory neurons) and reduces local vascular changes. Centrally, the mechanism involves suppressing prostaglandin synthesis within the hypothalamus, which effectively modulates the hypothalamic thermal set point. These simultaneous actions across anatomical domains lead directly to the drug's established physiological consequence.

Mechanistic Constraints: Reversibility and Non-Selectivity

The scope of the mechanism is constrained by its inherent properties. The reversible binding of Ibuprofen to the COX enzymes dictates that the inhibitory effect is reversible and time-dependent, which influences the concentration required for sustained action. Furthermore, the drug's non-selective nature means that inhibition affects both inflammation-driving COX-2 and the COX-1 enzyme, which is responsible for synthesizing mediators crucial for several physiological processes, like those involved in gastric mucosal protection and renal hemodynamics.

How to Use Ibuflam Lichtenstein

Ibuflam Lichtenstein is administered orally and its usage is guided by specific instructions. Adherence to these guidelines ensures consistency with the established protocols for administering the active substance, Ibuprofen. The preparation is available as film-coated tablets and an oral suspension, which determines the administration procedure.

---

Official Administration Guidelines

The usage protocol establishes the standard amount, timing, and conditions for taking the medicine.

Feature	Official Protocol
Route of Administration	Oral via tablet or suspension.
Standard Dosing Principle	Utilize the lowest effective dose for the shortest duration necessary for symptomatic relief.
Adult Dosing Range	Acute use typically begins at 200 mg to 400 mg per dose. The maximum daily dose is 3200 mg for prescription use, taken in divided doses.
Frequency	Dosing for acute relief is typically every 4 to 6 hours as needed, maintaining a minimum interval of 4 hours between doses.

---

Procedural and Population Requirements

Administration includes specific procedural steps and adjustments for certain patient groups. Tablets must be swallowed whole with fluid and should not be crushed, broken, or chewed. The medication should be taken with food or milk to mitigate potential gastrointestinal discomfort.

Pediatric dosing is calculated based on the child's body weight (typically 5 to 10 mg/kg per dose) using the oral suspension. Guidelines include close monitoring and considering a reduced dosage for patients with impaired renal function. If a dose is missed, it should be skipped, and the standard schedule should be resumed; a double dose must not be taken.

Research Evidence / Overview of Studies for Ibuflam Lichtenstein

---

Evidence for Managing Mild to Moderate Acute Pain

Research for addressing acute physical discomfort (such as headache and muscle issues) primarily consists of short-term Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies focused on how patient-reported discomfort intensity and the time required to see a change in those measurements were evaluated. Studies conducted during periods of increased symptom activity reported patterns where the maximum observed change in discomfort measurements occurred within the first few hours of administration. The evidence base is fundamentally short-term, focusing on follow-up durations typically less than 24 hours, and provides limited information regarding extended-duration use.

Evidence for Antipyresis and Fever Reduction

Research exploring fever patterns was evaluated in trials designed to measure the impact on systemic temperature. These studies measured the observed change in body temperature, the time until that change was noted, and the duration over which the change was maintained. Research describes patterns where changes in temperature measurements were observed in adult and pediatric populations. The studies focus on temporary physiological imbalance and short-term symptom patterns, not extended disease progression.

Evidence for Chronic and Menstrual Symptom Relief

Research has explored symptom management in conditions characterized by fluctuating or episodic manifestations, such as primary dysmenorrhea. Studies examined patient-reported outcomes describing perceived discomfort. For chronic inflammatory states, research often involves observational settings evaluating daily-life functioning over intermediate periods, focusing on outcomes linked to inflammatory or irritative states and functional limitations. Findings help contextualize how patients reported their experience when the compound was studied for its effect on symptoms in these conditions.

Evidence in Special Populations

Research was evaluated in specific demographic groups, including children and older adults. The compound was studied for acute symptom patterns in children, particularly concerning fever. Furthermore, specialized research has studied its acute application in preterm infants for Patent Ductus Arteriosus (PDA) closure. Findings for older adult populations and those with certain underlying health conditions were observed in research, though data for certain subgroups remain insufficient when attempting to generalize from the main clinical trial populations.

Common questions about Ibuflam Lichtenstein (FAQ)

Q: What are the most common side effects of Drug X?

A: Official product information, based on clinical trials, summarizes common side effects. Common side effects reported in clinical trials include events such as headache, fatigue, and reactions at the injection site (if the medicine is administered as an injection). This information represents the effects most frequently observed.

---

Q: Can I take Drug X with a glass of wine or beer?

A: Regulatory documents address interactions with other substances, including alcohol. Official product information states that Drug X may enhance certain effects of alcohol, or vice-versa. The official labeling indicates that limiting or avoiding co-administration may be necessary due to potential central nervous system effects, such as increased drowsiness.

---

Q: Can children under 12 years old use Drug X?

A: According to the official product information, the safety and effectiveness of this medicine have not been established or studied in pediatric patients who are younger than 12 years of age. The official labeling does not include prescribing information for age groups outside of those for which the medicine is officially labeled.

---

Q: How should I store Drug X?

A: Official labeling provides specific instructions, typically advising that the medicine be stored at room temperature, which is often specified as 20°C to 25°C (68°F to 77°F), with permitted temporary excursions. It is also advised that the medicine be protected from exposure to light and excessive moisture.

---

Q: What should I do if I miss a dose?

A: The official Dosage and Administration section of the labeling provides guidance on how to manage a missed dose. The guidance provided often states that a missed dose may be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose (for example, within 8 hours), the guidance often suggests skipping the missed dose and continuing with the regular schedule.

---

Q: Is it safe to use Drug X long-term (over one year)?

A: The regulatory documents summarize the safety data gathered during the clinical trials. These trials often have a defined duration, such as 52 weeks. The official safety profile is based on the use within that trial duration, and specific data for use extending significantly beyond that time frame may not be fully characterized or available in the labeling.

---

Q: Does Drug X make you sleepy or affect driving?

A: Warnings and precautions in the official product information address potential effects on the nervous system. The label will indicate if the drug has been observed to cause effects like dizziness or somnolence (drowsiness). If these effects occur, the official information warns they may potentially impair the ability to drive or safely operate machinery.

Official Storage and Disposal Requirements

Storage of Ibuflam Lichtenstein must adhere strictly to regulatory conditions to ensure stability and quality. The medicine must be stored below 30 C and protected from both light and moisture. To maintain safety, all forms of the product must be kept out of the sight and reach of children.

Handling and Disposal

Ibuflam should not be used after the expiry date printed on the packaging. Liquid formulations, such as oral suspension, must be shaken well before use, and specific post-opening stability rules may apply. Regulatory guidance mandates that unused or expired Ibuflam must not be discarded via household waste or flushed into wastewater. Disposal of all waste material must be carried out in accordance with local environmental requirements, often requiring consultation with a pharmacist.